82 FR 47755 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 197 (October 13, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 197 (October 13, 2017)
| Page Range | 47755-47755 | |
| FR Document | 2017-22147 |
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)] [Notices] [Page 47755] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-22147] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows. Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes Description of Technology: The invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the development of obesity and its metabolic consequences, including insulin resistance and type 2 diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated activation of a macrophage-mediated inflammatory response. Conversely, rats treated with a peripheral CB1R antagonist restores normoglycemia and preserves beta-cell function. Similar results are seen following selective in vivo knockdown of macrophage CB1R by daily treatment of ZDF rats with the instant D-glucan-encapsulated CB1R Small interfering RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA may represent a new commecializable method of treating type-2 diabetes or preventing the progression of insulin resistance to overt diabetes. Potential Commercial Applications: Treatment of obesity, insulin resistance, and diabetes. Development Stage: In vivo data available. Inventors: George Kunos, Tony Jourdan (NIAAA), Michael Czech, Myriam Aouadi. Intellectual Property: HHS Reference No. E-103-2013/0, U.S. Provisional Patent Application 61/839,239 filed June 25, 2013, International Patent Application PCT/US2014/043924 filed June 24, 2014, European Patent Application 14818342.9 filed June 24, 2014 and U.S. Patent Application 14/900,951 filed June 24, 2014. Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; [email protected]. Dated: October 5, 2017. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2017-22147 Filed 10-12-17; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47755
Contact Person: Angela Y Ng, Ph.D., MBA, applications are filed on selected DEPARTMENT OF HEALTH AND
Scientific Review Officer, Center for inventions to extend market coverage HUMAN SERVICES
Scientific Review, National Institutes of for companies and may also be available
Health, 6701 Rockledge Drive, Room 6200, for licensing. A description of the National Institutes of Health
MSC 7804, Bethesda, MD 20892, 301–435–
1715, nga@csr.nih.gov.
technology follows.
National Institute of Neurological
Name of Committee: Center for Scientific Small Interfering RNA Inhibition of Disorders and Stroke; Notice of Closed
Review Special Emphasis Panel; Pregnancy, Cannabanoid-1 Receptor (CB1R) for Meetings
Placentation, and Neonatology. Treating Type 2 Diabetes
Date: November 9, 2017. Pursuant to section 10(d) of the
Time: 1:00 p.m. to 4:00 p.m. Description of Technology: The Federal Advisory Committee Act, as
Agenda: To review and evaluate grant invention pertains to the use of glucan
amended, notice is hereby given of the
applications. encapsulated non-immunostimulatory
following meetings.
Place: National Institutes of Health, 6701 small interfering RNAs (siRNAs) to treat The meetings will be closed to the
Rockledge Drive, Bethesda, MD 20892 type-2 diabetes. Endocannabinoids (EC) public in accordance with the
(Virtual Meeting). are lipid signaling molecules that act on
Contact Person: Gary Hunnicutt, Ph.D.,
provisions set forth in sections
the same cannabinoid receptors that 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Scientific Review Officer, Center for recognize and mediate the effects of
Scientific Review, National Institutes of as amended. The grant applications and
endo- and phytocannabanoids. EC the discussions could disclose
Health, 6701 Rockledge Drive, Room 6164,
receptor CB1R activation is implicated
MSC 7892, Bethesda, MD 20892, 301–435– confidential trade secrets or commercial
0229, gary.hunnicutt@nih.gov. in the development of obesity and its
property such as patentable material,
metabolic consequences, including
(Catalogue of Federal Domestic Assistance and personal information concerning
Program Nos. 93.306, Comparative Medicine; insulin resistance and type 2 diabetes.
individuals associated with the grant
93.333, Clinical Research, 93.306, 93.333, Beta-cell loss has been demonstrated in
applications, the disclosure of which
93.337, 93.393–93.396, 93.837–93.844, a Zucker diabetic fatty (ZDF) rat model
would constitute a clearly unwarranted
93.846–93.878, 93.892, 93.893, National of type-2 diabetes through CB1R-
invasion of personal privacy.
Institutes of Health, HHS) mediated activation of a macrophage-
mediated inflammatory response. Name of Committee: Neurological Sciences
Dated: October 6, 2017. Training Initial Review Group; NST–2
Anna Snouffer,
Conversely, rats treated with a
Subcommittee.
peripheral CB1R antagonist restores
Deputy Director, Office of Federal Advisory Date: October 23, 2017.
normoglycemia and preserves beta-cell Time: 8:00 a.m. to 6:00 p.m.
Committee Policy.
function. Similar results are seen Agenda: To review and evaluate grant
[FR Doc. 2017–22139 Filed 10–12–17; 8:45 am]
following selective in vivo knockdown applications.
BILLING CODE 4140–01–P
of macrophage CB1R by daily treatment Place: Hilton Crystal City, 2399 Jefferson
of ZDF rats with the instant D-glucan- Davis Highway, Arlington, VA 22202.
encapsulated CB1R Small interfering Contact Person: Elizabeth Webber, Ph.D.,
DEPARTMENT OF HEALTH AND RNA (siRNA). Knock-down of CB1R Scientific Review Officer, Scientific Review
HUMAN SERVICES with using glucan encapsulated siRNA Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
National Institutes of Health may represent a new commecializable MSC 9529, Bethesda, MD 20892–9529, (301)
method of treating type-2 diabetes or 496–1917, Webbere@mail.nih.gov.
Government-Owned Inventions; preventing the progression of insulin This notice is being published less than 15
Availability for Licensing resistance to overt diabetes. days prior to the meeting due to the timing
Potential Commercial Applications: limitations imposed by the review and
AGENCY: National Institutes of Health, Treatment of obesity, insulin resistance, funding cycle.
HHS. and diabetes. Name of Committee: National Institute of
ACTION: Notice. Development Stage: In vivo data Neurological Disorders and Stroke Special
available. Emphasis Panel; R13 Review.
SUMMARY: The inventions listed below Inventors: George Kunos, Tony Date: October 26, 2017.
are owned by an agency of the U.S. Jourdan (NIAAA), Michael Czech, Time: 9:00 a.m. to 4:00 p.m.
Government and are available for Myriam Aouadi. Agenda: To review and evaluate grant
licensing in the U.S. Intellectual Property: HHS Reference applications.
FOR FURTHER INFORMATION CONTACT: No. E–103–2013/0, U.S. Provisional Place: National Institutes of Health,
Licensing information and copies of the Patent Application 61/839,239 filed Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
patent applications listed below may be June 25, 2013, International Patent Meeting).
obtained by emailing the indicated Application PCT/US2014/043924 filed
Contact Person: Ernie Lyons, Ph.D.,
licensing contact at the National Heart, June 24, 2014, European Patent Scientific Review Officer, Scientific Review
Lung, and Blood, Office of Technology Application 14818342.9 filed June 24, Branch, NINDS/NIH/DHHS, Neuroscience
Transfer and Development Office of 2014 and U.S. Patent Application 14/ Center, 6001 Executive Blvd., Suite 3204,
Technology Transfer, 31 Center Drive 900,951 filed June 24, 2014. MSC 9529, Bethesda, MD 20892–9529, (301)
Room 4A29, MSC2479, Bethesda, MD Licensing Contact: Michael 496–4056, lyonse@ninds.nih.gov.
20892–2479; telephone: 301–402–5579. Shmilovich, Esq, CLP; 301–435–5019; This notice is being published less than 15
A signed Confidential Disclosure shmilovm@nih.gov. days prior to the meeting due to the timing
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Agreement may be required to receive Dated: October 5, 2017. limitations imposed by the review and
copies of the patent applications. funding cycle.
Michael Shmilovich,
SUPPLEMENTARY INFORMATION: This Name of Committee: National Institute of
Senior Licensing and Patenting Manager,
Neurological Disorders and Stroke Special
notice is in accordance with 35 U.S.C. National Heart, Lung, and Blood Institute,
Emphasis Panel; F32 and K22 Review.
209 and 37 CFR part 404 to achieve Office of Technology Transfer and Date: November 2–3, 2017.
commercialization of results of Development. Time: 8:00 a.m. to 12:00 p.m.
federally-funded research and [FR Doc. 2017–22147 Filed 10–12–17; 8:45 am] Agenda: To review and evaluate grant
development. Foreign patent BILLING CODE 4140–01–P applications.
VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1](https://thefederalregister.org/doc/82_FR_47952/page/1.svg)
Document Created: 2017-10-13 04:33:18
Document Modified: 2017-10-13 04:33:18
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. | |
| FR Citation | 82 FR 47755 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR